
|Videos|June 29, 2017
Dr. Ascierto on Sequencing of Targeted Therapies for Melanoma
Author(s)Paolo A. Ascierto, MD
Paolo A. Ascierto, MD, National Tumour Institutue “Fondazione G. Pascale,” Unit of Melanoma, Naples, Italy, discusses the sequencing of targeted therapies for patients with melanoma.
Advertisement
Paolo A. Ascierto, MD, National Tumour Institutue “Fondazione G. Pascale,” Unit of Melanoma, Naples, Italy, discusses the sequencing of targeted therapies for patients with melanoma.
There are several clinical trials investigating the sequencing of targeted therapies, explains Ascierto. There is a particular trial looking at the sequencing of the encorafenib and binimetinib combination, nivolumab (Opdivo) and ipilimumab (Yeroy) combination, and a third arm of immunotherapy in between targeted therapy agents.
<<<
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate Cancer
2
Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer
3
Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Cancer
4
ADCs Reshape the Future of Lung Cancer Care: From Second-Line Therapy to Earlier Intervention
5





















































